CTXR Citius Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CTXR

Price (delayed)

$0.7

Market cap

$111.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.26

Enterprise value

$91.41M

Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.

Highlights
CTXR's debt is down by 32% YoY and by 11% QoQ
Citius Pharmaceuticals's quick ratio has shrunk by 55% YoY and by 20% QoQ
The EPS has declined by 44% year-on-year and by 18% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.citiuspharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CTXR
Market
Shares outstanding
159.09M
Market cap
$111.37M
Enterprise value
$91.41M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.31
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$37.6M
EBITDA
-$37.41M
Free cash flow
-$30.37M
Per share
EPS
-$0.26
Free cash flow per share
-$0.19
Book value per share
$0.53
Revenue per share
$0
TBVPS
$0.55
Balance sheet
Total assets
$97.4M
Total liabilities
$12.07M
Debt
$428,569
Equity
$84.73M
Working capital
$22.63M
Liquidity
Debt to equity
0.01
Current ratio
5.06
Quick ratio
3.65
Net debt/EBITDA
0.53
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-37.9%
Return on equity
-43.2%
Return on invested capital
-60.7%
Return on capital employed
-41%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CTXR stock price

How has the Citius Pharmaceuticals stock price performed over time
Intraday
-1.41%
1 week
6.06%
1 month
-27.45%
1 year
-53.02%
YTD
-7.47%
QTD
-21.99%

Financial performance

How have Citius Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$38.82M
Net income
-$38.18M
Gross margin
N/A
Net margin
N/A
The net income is down by 36% year-on-year and by 17% since the previous quarter
The operating income fell by 24% YoY and by 6% QoQ

Growth

What is Citius Pharmaceuticals's growth rate over time

Valuation

What is Citius Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 44% year-on-year and by 18% since the previous quarter
The price to book (P/B) is 18% lower than the 5-year quarterly average of 1.6 and 18% lower than the last 4 quarters average of 1.6
Citius Pharmaceuticals's equity has decreased by 16% YoY and by 7% QoQ

Efficiency

How efficient is Citius Pharmaceuticals business performance
CTXR's ROE has plunged by 66% YoY and by 22% from the previous quarter
The company's return on assets has shrunk by 61% YoY and by 21% QoQ
The ROIC has contracted by 33% YoY and by 17% from the previous quarter

Dividends

What is CTXR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CTXR.

Financial health

How did Citius Pharmaceuticals financials performed over time
Citius Pharmaceuticals's quick ratio has shrunk by 55% YoY and by 20% QoQ
Citius Pharmaceuticals's current ratio has decreased by 46% YoY and by 15% QoQ
CTXR's debt is 99% lower than its equity
CTXR's debt is down by 32% YoY and by 11% QoQ
Citius Pharmaceuticals's equity has decreased by 16% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.